Mirabegron 25 mg for Treatment of Primary Nocturnal Enuresis

• Status: Recruiting
• Trial end date: 2023-08-01
• Target enrollment: 0
• Participant gender: All

Summary

we will study the efficacy and safety of mirabegron25 in treatment of primary nocturnal enuresis in comparison to oral desmopressin 120 mcg and behavioral therapy

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Benha University
• Treatments: Deamino Arginine Vasopressin; Mirabegron

Criteria

Inclusion Criteria:

• primary nocturnal enuresis,

• negligible daytime wetting,

• wet at least 4 times over 4 weeks

• normal clinical examination with no neurological or urological cause for the enuresis

Exclusion Criteria:

• secondary enuresis, polysymptomatic

• neurologic bladder, neurological disorders,

• urinary incontinence disorders

• previous anti NE drugs.